ALVO: Rounding Bottom detected on 8 Oct 2026

ALVO is forming a rounding bottom pattern with current price at $5.85, trading 98.98% above its 52-week low but 35.32% below the 52-week high. The pattern shows solid structure (12.0), breakout (13.0), and volume (11.0) scores totaling 36.0 on the quality dimension. Key resistance sits at $5.04, with key support at $2.94. The setup scores 73 overall with 68.96% win probability. Volume remains subdued at 64% of the 20-day average, suggesting potential for explosive confirmation if institutional buying materializes. RSI at 57.37 indicates neutral momentum with room to run higher without overbought conditions. The measured move target is $6.17.

On October 6, 2026, Alvotech announced a long-term agreement with LOTTE Biologics to increase production capacity at its Syracuse, New York facility by 40,000 liters, providing a near-term bullish catalyst just two days before this pattern detection. Earlier, the Reykjavik facility's surveillance inspection was closed with a VAI classification, and four BLA resubmissions are under review with expected decisions in Q4 2026, positioning the company for potential FDA approvals. However, the company reported Q2 2026 earnings of -$0.11 per share, missing estimates of -$0.03, and revenue of $105.9 million, missing estimates of $113.2 million. 42 institutional investors added shares to their portfolio, while 30 decreased positions in their most recent quarter, reflecting mixed sentiment despite recent manufacturing and regulatory progress.

A successful breakout above the $5.04 resistance level would target $6.17 based on the measured move. The pattern suggests sustained volume above the 20-day average (~1.36M shares) would confirm breakout validity. The invalidation level sits at $2.94 key support—breach below this level would signal pattern failure and eliminate the bullish premise. With a 68.96% win probability, the setup indicates slightly better-than-average odds for upside follow-through. The structure indicates this consolidation has built sufficient energy for a move toward the conservative target within 4-8 weeks.

First-half revenue fell 31% to $212 million and adjusted EBITDA declined to $47 million, as facility upgrades temporarily reduced manufacturing output, creating near-term earnings headwinds despite guidance maintenance. Weak financial performance including losses, negative cash flow, and high leverage/negative equity poses fundamental risk. The company has four BLA decisions pending in Q4 2026—any FDA rejections or delayed approvals would torpedo momentum. Volume ratio of 0.63 and relative volume of 0.64 suggest low participation; insufficient institutional accumulation could abort the breakout. Low beta (0.13) indicates ALVO trades independently of market moves, limiting sector tailwinds from the bullish healthcare regime currently favorable at 0.59.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.